Navigation Links
ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Date:5/7/2008

Microbix to Acquire Commercialized Thrombolytic and Related Assets for $17

Million

TUCSON, Ariz., May 7 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that it has signed a letter of intent in which Microbix Biosystems will acquire urokinase inventory and related assets from ImaRx for $17 million in cash. Urokinase is an FDA-approved thrombolytic, or clot-dissolving agent, indicated for the treatment of acute massive pulmonary embolism. ImaRx acquired an approximate four year inventory of the product from Abbott Laboratories and has been selling the product from inventory since 2006.

Bradford A. Zakes, President and CEO of ImaRx, stated, "The proceeds to be generated through this transaction provide ImaRx with a solid source of non- dilutive financing. We are very pleased with the terms under which we have reached agreement with Microbix on the sale of our urokinase asset. Through this transaction, ImaRx will have gained access to operating capital under favorable economic terms that will enable the company to continue the advancement of our core SonoLysis technology."

Under terms of the agreement, Microbix will acquire the urokinase product and related assets for an upfront payment of $12 million plus an additional $5 million upon achievement of an inventory stability milestone. Upon closing, Microbix will assume full responsibility for urokinase, including sales, marketing and regulatory compliance requirements. To facilitate the inventory stability milestone, Microbix will engage ImaRx in a support services agreement.

ImaRx had previously announced in January 2008 that it had signed a letter of intent to partner with Microbix in the transfer
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
2. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
3. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
4. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
5. ImaRx to Report Corporate Updates and 4Q07 Financial Results
6. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
7. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
8. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
9. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
10. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
11. United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Many have long discussed the ... acne. Recently physicians from Clinical Psychiatry.com readdressed ... the skin, and suggested using hypnotherapy and ... produced from stress that cause acne. , Doctors in ... acne brings about, stress causes changes in the skin ...
(Date:5/21/2013)... Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused ... today that Jeffrey Riley , CEO, will ... Conference on Thursday, May 30, 2013 in New ... Riley is scheduled to present at 10:00 a.m. (Eastern Time). ... be accessed by logging onto the web at http://wsw.com/webcast/marcum/syn/ ...
(Date:5/21/2013)... Revolutionary Science, the manufacturer of the ... that they have expanded their colony counter product line ... InCount and ImpressCount. These affordable colony counters that ... food microbiology and pharmaceutical manufacturing. , The previously released ... bright white enclosure with jet black accents represent the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Vital ... the University of California, San Diego for a joint ... bearing Gravitic™ MRI (Magnetic Resonance Imaging) with that of ... for its continued pursuit of improved healthcare by combining ... MRI is an extremely valuable tool for evaluating pathological ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3
... 2011 China PharmaHub Corp. (OTC Bulletin Board: ... today announced that it has signed a exclusive worldwide ... rights to develop, commercialize and market a universal donor ... UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa ...
... FREMONT, Calif. and SAN CARLOS, Calif., March 21, ... WGBS ), a leading developer of ... a leader in innovative genomic samples preparation, today ... integrated workflows for gene expression profiling and target ...
... N.J., March 21, 2011 Intrasphere Technologies ( ... solutions firm that provides services to Life Sciences ... SafetyXpress for Argus is Intrasphere,s proprietary implementation accelerator ... Safety suite. Intrasphere is a Specialized Oracle Argus ...
Cached Biology Technology:China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 3WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 4Intrasphere Technologies Launches SafetyXpress(TM) for Oracle(R) Argus Safety 2
(Date:5/21/2013)... scientists have charted the path of insulin action in ... a comprehensive blueprint for understanding what goes wrong in ... Humphrey and Professor David James from Sydney,s Garvan Institute ... online edition of the prestigious journal Cell Metabolism ... plays a very important role in the body because ...
(Date:5/20/2013)... effect of physical education (PE) on child weight, but ... the amount of time that elementary schoolchildren spent in ... study represents some of the first evidence of a ... forthcoming in the Journal of Health Economics . ... be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The research ...
(Date:5/20/2013)... Bristol and published online today in the Journal ... brain and inner ear developed in dinosaurs. , ... with Tom Hbner from the Niederschsische Landesmuseum in Hannover, ... dinosaurs. , The two palaeontologists studied different fossils of ... young (juvenile) individual of approximately three years of ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2Fossil brain teaser 2
... German . , What is the role of phosphorus ... for the nutrition and balance of a forest ecosystem? How can ... in mobile internet access? How do the modern arts experience, perceive ... the interpretation of artistic creations in general? These are just some ...
... shrink diagnostics to fit in a person,s pocket, one question ... liquid. University of Washington researchers have built and patented a ... conduct medical or environmental tests., "This allows us to move ... of layout that we want," said Karl Bhringer, a UW ...
... life scientists from Europe and around the world were ... Forty-eight of the researchers are from Europe and neighbouring ... and the United States join as Associate Members. In ... in the international scientific community. EMBO elects new ...
Cached Biology News:DFG establishes 10 new priority programs 2DFG establishes 10 new priority programs 3Portable diagnostics designed to be shaken, not stirred 2
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: